Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
New AI model from Caris and ECOG-ACRIN predicts breast cancer relapse up to 15 years
Why this collaboration marks a turning point for AI-driven breast cancer diagnostics The ECOG-ACRIN Cancer Research Group and Caris Life Sciences have released early findings from a large-scale collaboration aimed at transforming how recurrence risk is predicted in early-stage breast cancer. Presented at the 2025 San Antonio Breast Cancer Symposium, the joint effort has produced